Revvity (NYSE:RVTY) Updates FY 2026 Earnings Guidance

Revvity (NYSE:RVTY) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.300-5.400 for the period, compared to the consensus estimate of 5.250. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RVTY shares. Sanford C. Bernstein assumed coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price for the company. Barclays raised their price target on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. TD Cowen reissued a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Finally, The Goldman Sachs Group reduced their target price on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $108.36.

Revvity Stock Performance

NYSE RVTY traded up $2.98 during trading hours on Wednesday, hitting $114.37. The company had a trading volume of 517,853 shares, compared to its average volume of 1,382,933. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $118.30. The firm has a market cap of $12.76 billion, a P/E ratio of 54.72, a price-to-earnings-growth ratio of 2.27 and a beta of 1.07. The business has a fifty day simple moving average of $107.16 and a 200-day simple moving average of $99.91. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. The business had revenue of $711.00 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Revvity will post 5.25 EPS for the current year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is 13.40%.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Quarterly earnings beat expectations: Revvity reported adjusted EPS of $1.41, above analyst estimates of approximately $1.21–$1.23 and up from $1.18 a year earlier. Revenue of $711 million also exceeded the roughly $703 million consensus. Revvity raises annual profit and revenue forecasts
• Positive Sentiment: 2026 guidance was raised: The company now expects full-year EPS of $5.30–$5.40, above the $5.25 analyst consensus, and revenue of $2.8–$2.9 billion. Wider margins and strong cash flow also supported the improved outlook. RVTY Q2 earnings beat estimates
• Positive Sentiment: Diagnostics demand is strengthening: Growth in diagnostics, along with improving demand for drug-development products, was a key driver of the quarter and is helping reinforce management’s more optimistic outlook. AI-related demand is also being viewed as a potential growth contributor. RVTY Q2 deep dive
• Negative Sentiment: Revenue declined modestly year over year: Quarterly sales fell 1.3% from the prior-year period, indicating that the recovery remains uneven despite the earnings beat and stronger diagnostic demand. Revvity earnings report

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RVTY. Pacer Advisors Inc. boosted its position in shares of Revvity by 4.7% during the fourth quarter. Pacer Advisors Inc. now owns 11,152 shares of the company’s stock worth $1,079,000 after buying an additional 504 shares during the period. Virtu Financial LLC acquired a new position in shares of Revvity in the fourth quarter valued at $384,000. Corient Private Wealth LLC grew its holdings in Revvity by 985.8% in the 4th quarter. Corient Private Wealth LLC now owns 126,664 shares of the company’s stock valued at $12,245,000 after buying an additional 114,999 shares in the last quarter. Alberta Investment Management Corp acquired a new position in shares of Revvity in the fourth quarter valued at about $1,442,000. Finally, Mercer Global Advisors Inc. ADV raised its position in shares of Revvity by 10.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 15,656 shares of the company’s stock valued at $1,515,000 after buying an additional 1,480 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.